Pfizer is closing in on a potential $7.3bn takeover of anti-obesity drug developer Metsera in what would be the biggest deal yet by a large
PREMIUM
Upgrade to read this Financial Times article and get so much more.
A Silver or Gold subscription plan is required to access premium news articles.
Upgrade
Already have a subscription? Sign in
Pfizer closes in on $7.3B takeover of anti-obesity drugmaker Metsera
Published 1 month ago
Sep 22, 2025 at 7:43 AM
Positive
Auto